LEVITEE LABS INC - LVTTF STOCK NEWS

Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) has announced a distribution agreement with Body Energy Club, a prominent health supplement retailer in Canada. This agreement allows Body Energy Club to offer MONKE Nutraceuticals™ products, including MONKE Mind and MONKE Body, at selected locations and online. Body Energy Club operates 17 retail locations and is known for its quality product selection. The partnership aims to enhance product visibility through in-store demonstrations and a social media campaign, aligning with the growing consumer focus on health post-COVID-19.

Levitee Labs has entered a strategic partnership with Canntab Therapeutics to enhance pain management alternatives in Canada. Under the agreement, Levitee will promote Canntab's cannabinoid-based products in its clinics and pharmacies across Alberta and British Columbia, aiming to address the opioid crisis. The collaboration is expected to improve patient care and boost revenue. Levitee operates five addiction clinics and three pharmacies, having served over 35,000 patients in the last year. Both companies foresee potential expansions into new therapeutic verticals in the future.

Levitee Labs Inc. (OTC: LVTTF) has announced the formation of a Medical Advisory Board, focusing on mental health and addiction treatment. This board comprises experts in diverse fields, set to enhance the company’s integrative wellness model through innovative solutions for addiction disorders.

The initiative aligns with Levitee's plans to acquire addiction-focused clinics and pharmacies in Alberta and British Columbia. CEO Pouya Farmand emphasized the company’s commitment to providing effective treatments as North America faces a mental health crisis exacerbated by the COVID-19 pandemic.

Levitee Labs has formed a Medical Advisory Board composed of leading experts in addiction, mental health, and drug development to enhance its integrative wellness model. This initiative aligns with Levitee's strategy to acquire addiction-focused clinics and pharmacies in Alberta and British Columbia. The company aims to address the rising mental health and addiction crises exacerbated by the COVID-19 pandemic, with opioid-related deaths increasing by 74%. Chief Executive Officer Pouya Farmand emphasizes the board's role in innovating treatment options, including psychedelics, to provide effective care for those in need.

Levitee Labs (OTC: LVTTF) has announced a collaboration with LiveRx to enhance access to Hepatitis C Virus (HCV) treatment in Alberta. The partnership will implement a patient-centric HCV care model by promoting screening and treatment across Levitee Clinics and Pharmacies. This initiative aims to address the 250,000 Canadians living with chronic HCV and the significant number unaware of their infection. With more than 95% effectiveness in curing HCV, the collaboration seeks to bridge the treatment gap for underserved populations, especially those with mental health conditions.

Levitee Labs Inc. has appointed Noha ElSayed as Executive Director of Levitee Clinics and Levitee Pharmacies in Alberta. With over 20 years of pharmacy experience, ElSayed specializes in addiction medicine and ketamine compounding. She will oversee the optimization of five clinics and three pharmacies, with expectations for expansions. The company aims to enhance operations and integrate new treatments for mental health and addiction. This strategic move aligns with Levitee’s goal of becoming a leader in integrative wellness through innovative therapies.

Levitee Labs has signed a letter of intent to acquire a chain of specialty addiction pharmacies in Vancouver, BC, for $4.0 million, based on a 4.7x multiple of a $850,000 annualized EBITDA. The chain operates three locations, expanding Levitee's portfolio in British Columbia. The acquisition involves a combined cash and stock payment, with an additional amount tied to post-closing performance. This marks Levitee's strategic move into a market significantly affected by the opioid crisis, as the company aims to enhance its presence in addiction treatment.

Levitee Labs reported combined revenues of $1,553,728 for September and October 2021, demonstrating consistent growth in its core divisions: Levitee Clinics (28.1%), Levitee Pharmacies (40.7%), and Earth Circle Organics (31.1%). Earth Circle's sales increased by 7.7% due to enhanced direct-to-consumer strategies. As the largest non-governmental addiction care provider in Alberta, Levitee aims to expand further through mergers and acquisitions and improve its revenue streams. CEO Pouya Farmand emphasized the importance of community impact alongside shareholder value.

Levitee Labs is acquiring a 51% stake in a new R&D compounding pharmacy in Calgary, Alberta. This pharmacy will focus on producing intranasal ketamine, sublingual preparations, and other Levitee-branded products aimed at mental health and pain management. The initiative enhances Levitee's operational capacity, allowing for the development of custom medications for specific health needs. CEO Pouya Farmand emphasized significant future growth potential through this acquisition, including expanding their product offerings and establishing a comprehensive R&D laboratory.